Cystic Fibrosis Prevalence in the United States and Participation in the Cystic Fibrosis Foundation Patient Registry in 2020

Overview

Journal J Cyst Fibros

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2023 Mar 15

PMID 36922288

Authors

Elizabeth A Cromwell

Joshua S Ostrenga

Jonathan V Todd

Alexander Elbert

A Whitney Brown

Albert Faro

Christopher H Goss

Bruce C Marshall

Affiliations

Soon will be listed here.

Abstract

Background: The Cystic Fibrosis Foundation Patient Registry (CFFPR) collects data on individuals with cystic fibrosis (CF) in the United States (US). In 2012, the US CF population was estimated at 33,292 to 34,327 individuals, with 81-84% CFFPR participation.

Methods: In this study, we update these estimates via simulation to account for uncertainty in CF incidence by race or Hispanic ethnicity, initiation of CF newborn screening (NBS) programs by state, and updated cumulative survival for CF births 1968-2020. We defined registry participation as the proportion of individuals alive as of 2020 with any prior CFFPR participation as well as the proportion with contributing data in 2019 or 2020; we summarize CFFPR participation for those born prior to 1968.

Results: We estimated the 2020 prevalent CF population between 1968-2020 to be 38,804 (95% Uncertainty Interval (UI): 38,532 to 39,065) individuals, with 77% of the prevalent CF population contributing recent data. CFFPR participation differs by age (54% of those born in 1968) and exceeds >90% of the population born in 2009 or later.

Conclusions: We demonstrate that the CFFPR remains a valid data source generalizable to the CF population. High participation among younger individuals may reflect the success of newborn screening programs and early referral to CF care. If engagement can be sustained, the percentage of individuals participating in the CFFPR will grow over time and there is an opportunity to identify factors associated with loss to follow up among older individuals to optimize the quality of the CFFPR data.

Citing Articles

Critical Issues in the Management of CRMS/CFSPID Children: A National Real-World Survey.

Terlizzi V, Fevola C, Presti S, Claut L, Ambroni M, Calderazzo M Pediatr Pulmonol. 2025; 60(1):e27483.

PMID: 39812351 PMC: 11734379. DOI: 10.1002/ppul.27483.

Health care transition recommendations for young people with intellectual and developmental disabilities and co-occurring mental health conditions: Stakeholder survey findings.

Mirzaian C, Deavenport-Saman A, Hudson S, Betz C Health Care Transit. 2024; 2:100075.

PMID: 39712583 PMC: 11657172. DOI: 10.1016/j.hctj.2024.100075.

Current landscape of cystic fibrosis gene therapy.

Plasschaert L, MacDonald K, Moffit J Front Pharmacol. 2024; 15:1476331.

PMID: 39439894 PMC: 11493704. DOI: 10.3389/fphar.2024.1476331.

The Real-World Effectiveness of Antifungals in People with Cystic Fibrosis and -Positive Cultures.

Faerber J, Kawut S, Hadjiliadis D, Hong G Ann Am Thorac Soc. 2024; 22(2):193-199.

PMID: 39388639 PMC: 11808554. DOI: 10.1513/AnnalsATS.202312-1070OC.

Linkage of the CF Foundation Patient Registry with the Scientific Registry of Transplant Recipients database.

Cromwell E, Ahn Y, Johnson P, Ramos K, Freeman A, Faro A J Cyst Fibros. 2024; 24(1):112-117.

PMID: 39358194 PMC: 11788025. DOI: 10.1016/j.jcf.2024.09.015.

References

Gokdemir Y, Karadag B . Sweat Testing and Recent Advances. Front Pediatr. 2021; 9:649904. PMC: 8129525. DOI: 10.3389/fped.2021.649904. View

Farrell P, Lai H, Li Z, Kosorok M, Laxova A, Green C . Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough!. J Pediatr. 2005; 147(3 Suppl):S30-6. DOI: 10.1016/j.jpeds.2005.08.012. View

Grosse S, Rosenfeld M, Devine O, Lai H, Farrell P . Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr. 2006; 149(3):362-6. DOI: 10.1016/j.jpeds.2006.04.059. View

Elborn J . Cystic fibrosis. Lancet. 2016; 388(10059):2519-2531. DOI: 10.1016/S0140-6736(16)00576-6. View

Friedman Ross L . Newborn screening for cystic fibrosis: a lesson in public health disparities. J Pediatr. 2008; 153(3):308-13. PMC: 2569148. DOI: 10.1016/j.jpeds.2008.04.061. View

Widerman E, Millner L, Sexauer W, Fiel S . Health status and sociodemographic characteristics of adults receiving a cystic fibrosis diagnosis after age 18 years. Chest. 2000; 118(2):427-33. DOI: 10.1378/chest.118.2.427. View

Scotet V, Gutierrez H, Farrell P . Newborn Screening for CF across the Globe-?. Int J Neonatal Screen. 2020; 6(1):18. PMC: 7422974. DOI: 10.3390/ijns6010018. View

Gentzsch M, Mall M . Ion Channel Modulators in Cystic Fibrosis. Chest. 2018; 154(2):383-393. PMC: 6113631. DOI: 10.1016/j.chest.2018.04.036. View

Stephenson A, Swaleh S, Sykes J, Stanojevic S, Ma X, Quon B . Contemporary cystic fibrosis incidence rates in Canada and the United States. J Cyst Fibros. 2022; 22(3):443-449. PMC: 11214606. DOI: 10.1016/j.jcf.2022.10.008. View

10.

Rosenfeld M, Ostrenga J, Cromwell E, Magaret A, Szczesniak R, Fink A . Real-world Associations of US Cystic Fibrosis Newborn Screening Programs With Nutritional and Pulmonary Outcomes. JAMA Pediatr. 2022; 176(10):990-999. PMC: 9344390. DOI: 10.1001/jamapediatrics.2022.2674. View

11.

Kloosterboer M, Hoffman G, Rock M, Gershan W, Laxova A, Li Z . Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics. 2009; 123(2):e338-46. DOI: 10.1542/peds.2008-1681. View

12.

Knapp E, Fink A, Goss C, Sewall A, Ostrenga J, Dowd C . The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry. Ann Am Thorac Soc. 2016; 13(7):1173-9. DOI: 10.1513/AnnalsATS.201511-781OC. View

13.

Massie J, Curnow L, Gaffney L, Carlin J, Francis I . Declining prevalence of cystic fibrosis since the introduction of newborn screening. Arch Dis Child. 2010; 95(7):531-3. DOI: 10.1136/adc.2009.172916. View

14.

Ostrenga J, Brown A, Todd J, Elbert A, Fink A, Faro A . Impact of loss to follow-up on survival estimation for cystic fibrosis. Ann Epidemiol. 2023; 86:98-103.e5. DOI: 10.1016/j.annepidem.2023.07.008. View

15.

Kosorok M, Wei W, Farrell P . The incidence of cystic fibrosis. Stat Med. 1996; 15(5):449-62. DOI: 10.1002/(SICI)1097-0258(19960315)15:5<449::AID-SIM173>3.0.CO;2-X. View

16.

Flanagin A, Frey T, Christiansen S, Bauchner H . The Reporting of Race and Ethnicity in Medical and Science Journals: Comments Invited. JAMA. 2021; 325(11):1049-1052. DOI: 10.1001/jama.2021.2104. View

17.

Guo J, Garratt A, Hill A . Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022; 21(3):456-462. DOI: 10.1016/j.jcf.2022.01.009. View

18.

Watts K, Layne B, Harris A, McColley S . Hispanic Infants with cystic fibrosis show low CFTR mutation detection rates in the Illinois newborn screening program. J Genet Couns. 2012; 21(5):671-5. DOI: 10.1007/s10897-012-9481-2. View

19.

Tuchman L, Schwartz L, Sawicki G, Britto M . Cystic fibrosis and transition to adult medical care. Pediatrics. 2010; 125(3):566-73. DOI: 10.1542/peds.2009-2791. View

20.

Dodge J, Lewis P, Stanton M, Wilsher J . Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J. 2006; 29(3):522-6. DOI: 10.1183/09031936.00099506. View